Translational Development Acquisition Corp. is a special purpose acquisition company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It currently has no significant operations. The company was incorporated to identify and combine with a suitable operating business.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | 1.5 | — |
| Q2 2025 | 0 | — | 1.6 | — |
| Q3 2025 | 0 | — | 1.7 | — |
| Q4 2025 | 0 | — | 1.6 | — |
| Q1 2026 | 0 | — | 1.3 | -10.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AN2 Therapeutics, Inc. (ANTX), Journey Medical Corporation (DERM), Oramed Pharmaceuticals Inc. (ORMP), Coherus Oncology, Inc. (CHRS), First Capital, Inc. (FCAP), PepGen Inc. (PEPG)